As B cell depletion using Rituximab has been successfully used for many years in lymphoma [26] and some autoimmune contexts [27], the expression of PLPP5 in B cells is not likely to be an insurmountable obstacle for an anti-PLPP5-based therapy for MM or Ab mediated autoimmunity. Here, PLPP5 is linked to Autoimmunity.